UK Biotech Ervaxx Launches With Focus On ‘Dark Antigens’
Start-Up Raises $17.5m In Series A
Melanoma is first target for company developing cancer vaccines and T-cell receptor immunotherapies.
You may also be interested in...
After receiving major backing for its strategy of targeting clonal neoantigens, Achilles's CEO tells Scrip that the UK firm's manufacturing prowess gives it an edge over competitors.
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.
The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth